Abstracts tagged "Antiphospholipid antibodies and systemic sclerosis"

Abstract Number: 1893 • 2016 ACR/ARHP Annual Meeting
Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis
Angélique Lemaire^1,2, Vincent Sobanski^2,3,4,5, Luc Dauchet⁶, Eric Hachulla^1,2,3,5, Sylvain Dubucquoi^3,5,7, Marc Lambert^1,2,3,5, Pierre-Yves Hatron^1,2,8 and David Launay^1,2,3,5, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, ³Inserm, U995, F-59000 Lille, France, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, ⁵Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁶CHU Lille, Service d’Epidémiologie, économie de la santé et prevention, F-59000 Lille, France, Lille, France, ⁷CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France, ⁸Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France
Background/Purpose: Antiphospholipid antibodies (aPL) can be present in the sera of systemic sclerosis (SSc) patients. Important variations of their prevalence are observed in the literature.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].